UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 502

Sortiert nach

Antitubercular drugs: possible role of natural products acting as antituberculosis medication in overcoming drug resistance and drug-induced hepatotoxicity

Naunyn-Schmiedeberg's archives of pharmacology, 2024-03, Vol.397 (3), p.1251-1273

2024

Link zum Volltext

Verfügbarkeit prüfen

Why Wait? The Case for Treating Tuberculosis with Inhaled Drugs

Pharmaceutical research, 2019-12, Vol.36 (12), p.166-6, Article 166

2019

Link zum Volltext

Verfügbarkeit prüfen

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy

European journal of clinical pharmacology, 2013-05, Vol.69 (5), p.1091-1101

2013

Link zum Volltext

Verfügbarkeit prüfen

Drug-induced lupus erythematosus

Archives of Dermatological Research, 2009, Vol.301 (1), p.99-105

2009

Link zum Volltext

Verfügbarkeit prüfen

Systematic review with network meta-analysis on the treatments for latent tuberculosis infection in children and adolescents

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2022-12, Vol.28 (12), p.1645-1653

2022

Link zum Volltext

Verfügbarkeit prüfen

Long-term efficacy of 6-month therapy with isoniazid and rifampin compared with isoniazid, rifampin, and pyrazinamide treatment for pleural tuberculosis

European journal of clinical microbiology & infectious diseases, 2019-11, Vol.38 (11), p.2121-2126

2019

Link zum Volltext

Verfügbarkeit prüfen

The coexistence of IgA vasculitis and tuberculosis: a case-based review

Rheumatology international, 2021-09, Vol.41 (9), p.1683-1689

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety of latent tuberculosis infection treatment in older patients with immune-mediated inflammatory diseases

Clinical rheumatology, 2022-03, Vol.41 (3), p.889-897

2022

Link zum Volltext

Verfügbarkeit prüfen

Safety of pyrazinamide-including regimen in late elderly patients with pulmonary tuberculosis: A prospective randomized open-label study

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2019-12, Vol.25 (12), p.1026-1030

2019

Link zum Volltext

Verfügbarkeit prüfen

Multi-Drug Resistant and Extensively-Drug Resistant Tuberculosis

Indian journal of pediatrics, 2020-10, Vol.87 (10), p.833-839

2020

Link zum Volltext

Verfügbarkeit prüfen

Addisonian Crisis Due to Antitubercular Therapy

Indian journal of pediatrics, 2015-09, Vol.82 (9), p.860-860

2015

Link zum Volltext

Verfügbarkeit prüfen

Polymorphisms in drug metabolism genes as a risk factor for first-line anti-tuberculosis drug-induced liver injury

Molecular biology reports, 2023-03, Vol.50 (3), p.2893-2900

2023

Link zum Volltext

Verfügbarkeit prüfen

Advances in the Diagnosis and Management of Tubercular Meningitis in Children

Indian journal of pediatrics, 2020, Vol.87 (1), p.26-33

2020

Link zum Volltext

Verfügbarkeit prüfen

Risk factors affecting the failure to complete treatment for patients with latent tuberculosis infection in Tokyo, Japan

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2020-11, Vol.26 (11), p.1129-1133

2020

Link zum Volltext

Verfügbarkeit prüfen

N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group

European journal of clinical pharmacology, 2014-09, Vol.70 (9), p.1079-1086

2014

Link zum Volltext

Verfügbarkeit prüfen

Longitudinal analysis of retinal nerve fiber layer and ganglion cell–inner plexiform layer thickness in ethambutol-induced optic neuropathy

Graefe's archive for clinical and experimental ophthalmology, 2015-12, Vol.253 (12), p.2293-2299

2015

Link zum Volltext

Verfügbarkeit prüfen

Revised Antituberculosis Drug Doses and Hepatotoxicity in HIV Negative Children

Indian journal of pediatrics, 2019-03, Vol.86 (3), p.229-232

2019

Link zum Volltext

Verfügbarkeit prüfen

Monitoring Treatment of Childhood Tuberculosis and the Role of Therapeutic Drug Monitoring

Indian journal of pediatrics, 2019-08, Vol.86 (8), p.732-739

2019

Link zum Volltext

Verfügbarkeit prüfen

CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis

European journal of clinical pharmacology, 2006-06, Vol.62 (6), p.423-429

2006

Link zum Volltext

Verfügbarkeit prüfen

Anti-tuberculosis treatments and risk of hepatocellular carcinoma in tuberculosis patients with liver cirrhosis: a population-based case–control study

European journal of clinical microbiology & infectious diseases, 2015-03, Vol.34 (3), p.479-485

2015

Link zum Volltext

Verfügbarkeit prüfen

GSTM1 and GSTT1 genetic polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity: an updated meta-analysis

European journal of clinical microbiology & infectious diseases, 2013-07, Vol.32 (7), p.859-868

2013

Link zum Volltext

Verfügbarkeit prüfen

Clinical Benefit of Delamanid (OPC-67683) in the Treatment of Multidrug-Resistant Tuberculosis Patients in China

Cell biochemistry and biophysics, 2013-12, Vol.67 (3), p.957-963

2013

Link zum Volltext

Verfügbarkeit prüfen

Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis

Molecular biology reports, 2013-05, Vol.40 (5), p.3591-3596

2013

Link zum Volltext

Verfügbarkeit prüfen

Increased incidence of liver enzymes abnormalities in patients treated with isoniazid in combination with disease modifying and/or biologic agents

Clinical rheumatology, 2014-08, Vol.33 (8), p.1049-1053

2014

Link zum Volltext

Verfügbarkeit prüfen

Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil

European journal of clinical pharmacology, 2008-07, Vol.64 (7), p.673-681

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 502

Suche als RSS-Feed

Aktive Filter

SpracheRussisch

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(472)
Mit Volltextzugriff
(478)

Publikationsform

Artikel
(502)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(434)
Life Sciences & Biomedicine
(411)
Humans
(352)
Male
(188)
Antitubercular Agents - Therapeutic Use
(174)
Tuberculosis
(170)
Female
(164)
Medicine
(164)
Biomedical And Life Sciences
(159)
Medicine & Public Health
(153)
Adult
(127)
Pharmacology & Pharmacy
(126)
Antitubercular Agents - Adverse Effects
(113)
Biomedicine
(110)
Middle Aged
(110)
Biochemistry
(105)
Pharmacology/toxicology
(91)
Infectious Diseases
(89)
Tuberculosis - Drug Therapy
(82)
Treatment Outcome
(75)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Antitubercular drugs: possible role of natural products acting as antituberculosis medication in overcoming drug resistance and drug-induced hepatotoxicity

Why Wait? The Case for Treating Tuberculosis with Inhaled Drugs

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy

Drug-induced lupus erythematosus

Systematic review with network meta-analysis on the treatments for latent tuberculosis infection in children and adolescents

Long-term efficacy of 6-month therapy with isoniazid and rifampin compared with isoniazid, rifampin, and pyrazinamide treatment for pleural tuberculosis

The coexistence of IgA vasculitis and tuberculosis: a case-based review

Safety of latent tuberculosis infection treatment in older patients with immune-mediated inflammatory diseases

Safety of pyrazinamide-including regimen in late elderly patients with pulmonary tuberculosis: A prospective randomized open-label study

Multi-Drug Resistant and Extensively-Drug Resistant Tuberculosis

Addisonian Crisis Due to Antitubercular Therapy

Polymorphisms in drug metabolism genes as a risk factor for first-line anti-tuberculosis drug-induced liver injury

Advances in the Diagnosis and Management of Tubercular Meningitis in Children

Risk factors affecting the failure to complete treatment for patients with latent tuberculosis infection in Tokyo, Japan

N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group

Longitudinal analysis of retinal nerve fiber layer and ganglion cell–inner plexiform layer thickness in ethambutol-induced optic neuropathy

Revised Antituberculosis Drug Doses and Hepatotoxicity in HIV Negative Children

Monitoring Treatment of Childhood Tuberculosis and the Role of Therapeutic Drug Monitoring

CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis

Anti-tuberculosis treatments and risk of hepatocellular carcinoma in tuberculosis patients with liver cirrhosis: a population-based case–control study

GSTM1 and GSTT1 genetic polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity: an updated meta-analysis

Clinical Benefit of Delamanid (OPC-67683) in the Treatment of Multidrug-Resistant Tuberculosis Patients in China

Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis

Increased incidence of liver enzymes abnormalities in patients treated with isoniazid in combination with disease modifying and/or biologic agents

Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil

Aktive Filter

Suchergebnisse filtern